Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Am Heart J ; 262: 131-139, 2023 Aug.
Article in English | MEDLINE | ID: covidwho-2293575


BACKGROUND: Neurocognitive dysfunction (NCD) is a common comorbidity among children with congenital heart disease (CHD). However, it is unclear how underlying CHD and its sequelae combine with genetics and acquired cardiovascular and neurological disease to impact NCD and outcomes across the lifespan in adults with CHD. METHODS: The Multi-Institutional Neurocognitive Discovery Study in Adults with Congenital Heart Disease (MINDS-ACHD) is a partnership between the Pediatric Heart Network (PHN) and the Adult Alliance for Research in Congenital Cardiology (AARCC) that examines objective and subjective neurocognitive function and genetics in young ACHD. This multicenter cross-sectional pilot study is enrolling 500 young adults between 18 and 30 years with moderate or severe complexity CHD at 14 centers in North America. Enrollment includes 4 groups (125 participants each): (1) d-looped Transposition of the Great Arteries (d-TGA); (2) Tetralogy of Fallot (TOF); (3) single ventricle (SV) physiology; and (4) "other moderately or severely complex CHD." Participants complete the standardized tests from the NIH Toolbox Cognitive Battery, the NeuroQoL, the Hospital Anxiety and Depression Scale, and the PROMIS Global QoL measure. Clinical and demographic variables are collected by interview and medical record review, and an optional biospecimen is collected for genetic analysis. Due to the COVID-19 pandemic, participation may be done remotely. Tests are reviewed by a Neurocognitive Core Laboratory. CONCLUSIONS: MINDS-ACHD is the largest study to date characterizing NCD in young adults with moderate or severely complex CHD in North America. Its results will provide valuable data to inform screening and management strategies for NCD in ACHD and improve lifelong care.

COVID-19 , Heart Defects, Congenital , Noncommunicable Diseases , Transposition of Great Vessels , Young Adult , Humans , Adult , Child , Heart Defects, Congenital/epidemiology , Transposition of Great Vessels/complications , Cross-Sectional Studies , Pandemics , Pilot Projects , Quality of Life , COVID-19/complications
World J Pediatr Congenit Heart Surg ; 12(4): 554-556, 2021 07.
Article in English | MEDLINE | ID: covidwho-1140469


A six-week-old infant presented in extremis and was diagnosed with dextro-transposition of the great arteries, intact ventricular septum, features of left ventricular deconditioning, and abnormal coronary arteries. Treatment with prostaglandin E1 and balloon atrial septostomy was insufficient, necessitating extracorporeal membrane oxygenation (ECMO). Severe acute respiratory syndrome coronavirus-2 was detected. The arterial switch operation was delayed by eight days because of COVID-19. Although stable on ECMO, the infant was treated with remdesivir. Extracorporeal membrane oxygenation was not required postoperatively with chest closure on day 2 and extubation on day 5.

Arterial Switch Operation , COVID-19 , Transposition of Great Vessels , COVID-19/complications , Coronary Vessels , Humans , Infant , SARS-CoV-2 , Transposition of Great Vessels/complications , Transposition of Great Vessels/diagnostic imaging , Transposition of Great Vessels/surgery , Treatment Outcome